Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Thuresson M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Wittbrodt E, Hammar N, Fenici P, Kosiborod M; CVD-REAL Investigators and Study Group. Thuresson M, et al. Among authors: cavender ma. Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338. Diabetes Care. 2018. PMID: 29784708 No abstract available.
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group*. Kosiborod M, et al. Among authors: cavender ma. Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18. Circulation. 2017. PMID: 28522450 Free PMC article. Clinical Trial.
Canagliflozin: Cui Bono?
Cavender MA, Kosiborod M. Cavender MA, et al. Circulation. 2018 Jan 23;137(4):335-337. doi: 10.1161/CIRCULATIONAHA.117.032198. Epub 2017 Nov 13. Circulation. 2018. PMID: 29133603 No abstract available.
Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)".
Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jørgensen ME, Thuresson M, Arya N, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: cavender ma. Circulation. 2018 Feb 27;137(9):989-991. doi: 10.1161/CIRCULATIONAHA.117.031847. Circulation. 2018. PMID: 29483180 No abstract available.
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Jørgensen ME, Wittbrodt ET, Thuresson M, Bodegård J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: cavender ma. Diabetes Obes Metab. 2018 Aug;20(8):1983-1987. doi: 10.1111/dom.13299. Epub 2018 Apr 17. Diabetes Obes Metab. 2018. PMID: 29569378 Free PMC article.
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, Fu AZ, Bodegård J, Blak BT, Wittbrodt E, Thuresson M, Fenici P, Hammar N, Kosiborod M; CVD-REAL Investigators and Study Group. Cavender MA, et al. J Am Coll Cardiol. 2018 Jun 5;71(22):2497-2506. doi: 10.1016/j.jacc.2018.01.085. J Am Coll Cardiol. 2018. PMID: 29852973 Free article.
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Among authors: cavender ma. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry.
Wittbrodt E, Bhalla N, Andersson Sundell K, Gao Q, Dong L, Cavender MA, Hunt P, Wong ND, Mellström C. Wittbrodt E, et al. Among authors: cavender ma. Endocrinol Diabetes Metab. 2020 May 7;3(3):e00133. doi: 10.1002/edm2.133. eCollection 2020 Jul. Endocrinol Diabetes Metab. 2020. PMID: 32704557 Free PMC article.
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Tuttle KR, Brosius FC 3rd, Cavender MA, Fioretto P, Fowler KJ, Heerspink HJL, Manley T, McGuire DK, Molitch ME, Mottl AK, Perreault L, Rosas SE, Rossing P, Sola L, Vallon V, Wanner C, Perkovic V. Tuttle KR, et al. Among authors: cavender ma. Diabetes. 2021 Jan;70(1):1-16. doi: 10.2337/dbi20-0040. Epub 2020 Oct 26. Diabetes. 2021. PMID: 33106255 Free PMC article. Review.
115 results